{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T18:30:15Z","timestamp":1789065015386,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T00:00:00Z","timestamp":1748131200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T00:00:00Z","timestamp":1748131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7232288"],"award-info":[{"award-number":["7232288"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7232288"],"award-info":[{"award-number":["7232288"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-03192-4","type":"journal-article","created":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T02:50:48Z","timestamp":1748141448000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Analysis and mining of brodalumab adverse events based on FAERS database"],"prefix":"10.1038","volume":"15","author":[{"given":"Yue","family":"Wan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanhuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,25]]},"reference":[{"issue":"19","key":"3192_CR1","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong, A. W. & Read, C. Pathophysiology, clinical presentation, and treatment of psoriasis: A review. JAMA 323(19), 1945\u20131960. https:\/\/doi.org\/10.1001\/jama.2020.4006 (2020).","journal-title":"JAMA"},{"issue":"9997","key":"3192_CR2","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","volume":"386","author":"WH Boehncke","year":"2015","unstructured":"Boehncke, W. H. & Schon, M. P. Psoriasis. Lancet 386(9997), 983\u2013994. https:\/\/doi.org\/10.1016\/S0140-6736(14)61909-7 (2015).","journal-title":"Lancet"},{"issue":"1","key":"3192_CR3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jdermsci.2015.10.009","volume":"81","author":"H Nakagawa","year":"2016","unstructured":"Nakagawa, H., Niiro, H., Ootaki, K., Japanese brodalumab study group. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study. J. Dermatol. Sci. 81(1), 44\u201352. https:\/\/doi.org\/10.1016\/j.jdermsci.2015.10.009 (2016).","journal-title":"J. Dermatol. Sci."},{"key":"3192_CR4","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1111\/jdv.14913","volume":"32","author":"A Gottlieb","year":"2018","unstructured":"Gottlieb, A. et al. Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials. J. Eur. Acad. Dermatol. Venereol. 32, 1305\u20131313. https:\/\/doi.org\/10.1111\/jdv.14913 (2018).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"13","key":"3192_CR5","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","volume":"366","author":"KA Papp","year":"2012","unstructured":"Papp, K. A. et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N. Engl. J. Med. 366(13), 1181\u20131189. https:\/\/doi.org\/10.1056\/NEJMoa1109017 (2012).","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"3192_CR6","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.jaad.2014.08.039","volume":"71","author":"K Papp","year":"2014","unstructured":"Papp, K. et al. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J. Am. Acad. Dermatol. 71(6), 1183-1190.e3. https:\/\/doi.org\/10.1016\/j.jaad.2014.08.039 (2014).","journal-title":"J. Am. Acad. Dermatol."},{"key":"3192_CR7","doi-asserted-by":"publisher","first-page":"1124628","DOI":"10.3389\/fphar.2023.1124628","volume":"14","author":"Z Deng","year":"2023","unstructured":"Deng, Z., Wang, S., Wu, C. & Wang, C. IL-17 inhibitor-associated inflammatory bowel disease: A study based on literature and database analysis. Front Pharmacol. 14, 1124628. https:\/\/doi.org\/10.3389\/fphar.2023.1124628 (2023).","journal-title":"Front Pharmacol."},{"issue":"1","key":"3192_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/cpt.2155","volume":"110","author":"N Petitpain","year":"2021","unstructured":"Petitpain, N. et al. IL-17 inhibitors and inflammatory bowel diseases: A postmarketing study in vigibase. Clin. Pharmacol. Ther. 110(1), 159\u2013168. https:\/\/doi.org\/10.1002\/cpt.2155 (2021).","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"3192_CR9","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/ddg.14976","volume":"21","author":"L Mantovani","year":"2023","unstructured":"Mantovani, L. et al. A possible case of brodalumab-induced ichthyosis. J. Dtsch. Dermatol. Ges. 21(3), 288\u2013290. https:\/\/doi.org\/10.1111\/ddg.14976 (2023).","journal-title":"J. Dtsch. Dermatol. Ges."},{"issue":"6","key":"3192_CR10","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1272\/jnms.JNMS.2021_88-517","volume":"88","author":"S Okazaki","year":"2021","unstructured":"Okazaki, S., Hoashi, T., Saeki, H. & Kanda, N. A case of autoimmune hepatitis\/primary biliary cholangitis overlap syndrome during treatment with brodalumab for generalized pustular psoriasis. J. Nippon Med. Sch. 88(6), 569\u2013573. https:\/\/doi.org\/10.1272\/jnms.JNMS.2021_88-517 (2021).","journal-title":"J. Nippon Med. Sch."},{"issue":"5","key":"3192_CR11","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2165\/00002018-200326050-00001","volume":"26","author":"E Van Puijenbroek","year":"2003","unstructured":"Van Puijenbroek, E., Diemont, W. & van Grootheest, K. Application of quantitative signal detection in the Dutch spontaneous reporting system for adverse drug reactions. Drug Saf. 26(5), 293\u2013301. https:\/\/doi.org\/10.2165\/00002018-200326050-00001 (2003).","journal-title":"Drug Saf."},{"issue":"1","key":"3192_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP Van Puijenbroek","year":"2002","unstructured":"Van Puijenbroek, E. P. et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol. Drug Saf. 11(1), 3\u201310. https:\/\/doi.org\/10.1002\/pds.668 (2002).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"6","key":"3192_CR13","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans, S. J., Waller, P. C. & Davis, S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol. Drug Saf. 10(6), 483\u2013486. https:\/\/doi.org\/10.1002\/pds.677 (2001).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"4","key":"3192_CR14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate, A. et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur. J. Clin. Pharmacol. 54(4), 315\u2013321. https:\/\/doi.org\/10.1007\/s002280050466 (1998).","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"3","key":"3192_CR15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","volume":"53","author":"W Dumouchel","year":"1999","unstructured":"Dumouchel, W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am. Stat. 53(3), 177\u2013190. https:\/\/doi.org\/10.1080\/00031305.1999.10474456 (1999).","journal-title":"Am. Stat."},{"issue":"10","key":"3192_CR16","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/nrrheum.2014.123","volume":"10","author":"O Boyman","year":"2014","unstructured":"Boyman, O., Comte, D. & Spertini, F. Adverse reactions to biologic agents and their medical management. Nat. Rev. Rheumatol. 10(10), 612\u2013627. https:\/\/doi.org\/10.1038\/nrrheum.2014.123 (2014).","journal-title":"Nat. Rev. Rheumatol."},{"issue":"1","key":"3192_CR17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3109\/09546634.2013.878448","volume":"26","author":"G Brown","year":"2015","unstructured":"Brown, G., Malakouti, M., Wang, E., Koo, J. Y. & Levin, E. Anti-IL-17 phase II data for psoriasis: A review. J. Dermatolog. Treat. 26(1), 32\u201336. https:\/\/doi.org\/10.3109\/09546634.2013.878448 (2015).","journal-title":"J. Dermatolog. Treat."},{"issue":"9","key":"3192_CR18","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1080\/14740338.2024.2392007","volume":"23","author":"T Battista","year":"2024","unstructured":"Battista, T. et al. Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis. Expert Opin. Drug Saf. 23(9), 1115\u20131126. https:\/\/doi.org\/10.1080\/14740338.2024.2392007 (2024).","journal-title":"Expert Opin. Drug Saf."},{"key":"3192_CR19","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1111\/1346-8138.15826","volume":"48","author":"T Yamamoto","year":"2021","unstructured":"Yamamoto, T. Similarity and difference between palmoplantar pustulosis and pustular psoriasis. J. Dermatol. 48, 1346\u20138138. https:\/\/doi.org\/10.1111\/1346-8138.15826 (2021).","journal-title":"J. Dermatol."},{"issue":"2","key":"3192_CR20","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1684\/ejd.2020.3702","volume":"30","author":"R M\u00f6ssner","year":"2020","unstructured":"M\u00f6ssner, R. & Pinter, A. Paradoxical palmoplantar pustulosis induced by secukinumab and brodalumab: A report of three cases. Eur. J. Dermatol. 30(2), 177\u2013209. https:\/\/doi.org\/10.1684\/ejd.2020.3702 (2020).","journal-title":"Eur. J. Dermatol."},{"issue":"1","key":"3192_CR21","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/ced.13731","volume":"44","author":"S Dogra","year":"2019","unstructured":"Dogra, S., Bishnoi, A., Narang, T. & Handa, S. Secukinumab-induced paradoxical pustular psoriasis. Clin. Exp. Dermatol. 44(1), 72\u201373. https:\/\/doi.org\/10.1111\/ced.13731 (2019).","journal-title":"Clin. Exp. Dermatol."},{"issue":"840\u2013842","key":"3192_CR22","first-page":"844","volume":"27","author":"R Reid","year":"2013","unstructured":"Reid, R. & Friedberg, J. W. Management of marginal zone lymphoma. Oncology (Williston Park) 27(840\u2013842), 844 (2013).","journal-title":"Oncology (Williston Park)"},{"key":"3192_CR23","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.beha.2016.07.002","volume":"30","author":"P Sriskandarajah","year":"2017","unstructured":"Sriskandarajah, P. & Dearden, C. E. Epidemiology and environmental aspects of marginal zone lymphomas. Best Pract. Res. Clin. Haematol. 30, 84\u201391. https:\/\/doi.org\/10.1016\/j.beha.2016.07.002 (2017).","journal-title":"Best Pract. Res. Clin. Haematol."},{"issue":"10","key":"3192_CR24","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1002\/ajh.27058","volume":"98","author":"CY Cheah","year":"2023","unstructured":"Cheah, C. Y. & Seymour, J. F. Marginal zone lymphoma: 2023 update on diagnosis and management. Am. J. Hematol. 98(10), 1645\u20131657. https:\/\/doi.org\/10.1002\/ajh.27058 (2023).","journal-title":"Am. J. Hematol."},{"issue":"11","key":"3192_CR25","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1038\/jid.2009.113","volume":"129","author":"YB Brauchli","year":"2009","unstructured":"Brauchli, Y. B. et al. Psoriasis and risk of incident cancer: An inception cohort study with a nested case-control analysis. J. Invest. Dermatol. 129(11), 2604\u20132612. https:\/\/doi.org\/10.1038\/jid.2009.113 (2009).","journal-title":"J. Invest. Dermatol."},{"issue":"s3","key":"3192_CR26","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/jdv.12165","volume":"27","author":"C Pouplard","year":"2013","unstructured":"Pouplard, C. et al. Risk of cancer in psoriasis: A systematic review and meta-analysis of epidemiological studies. J. Eur. Acad. Dermatol. Venereol. 27(s3), 36\u201346. https:\/\/doi.org\/10.1111\/jdv.12165 (2013).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"8","key":"3192_CR27","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.ad.2019.02.005","volume":"110","author":"M Mu\u00f1oz-Torres","year":"2019","unstructured":"Mu\u00f1oz-Torres, M., Aguado, P., Daud\u00e9n, E., Carrascosa, J. M. & Rivera, R. Osteoporosis and psoriasis. Actas Dermosifiliogr (Engl Ed) 110(8), 642\u2013652. https:\/\/doi.org\/10.1016\/j.ad.2019.02.005 (2019).","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"3192_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcab116.011","author":"S Moussa","year":"2021","unstructured":"Moussa, S., Khaled, H., Elshishtawy, H. & Elnaggar, H. Subclinical atherosclerosis in psoriatic patients: Relation with vitamin D. QJM: Int. J. Med. https:\/\/doi.org\/10.1093\/qjmed\/hcab116.011 (2021).","journal-title":"QJM: Int. J. Med."},{"key":"3192_CR29","doi-asserted-by":"publisher","DOI":"10.1177\/2515690X231211663","author":"M Moosazadeh","year":"2023","unstructured":"Moosazadeh, M. et al. Comparing vitamin D level between patients with psoriasis and healthy individuals: A systematic review and meta-analysis. J. Evid.-Based Integrat. Med. https:\/\/doi.org\/10.1177\/2515690X231211663 (2023).","journal-title":"J. Evid.-Based Integrat. Med."},{"key":"3192_CR30","doi-asserted-by":"publisher","unstructured":"Gupta, S., Garg, P., & Gupta, N. Serum 25-hydroxyvitamin D level in psoriasis patients: A case-control study.\u00a0International Journal of Research in Dermatology.\u00a02019 https:\/\/doi.org\/10.18203\/ISSN.2455-4529.INTJRESDERMATOL20185500.","DOI":"10.18203\/ISSN.2455-4529.INTJRESDERMATOL20185500"},{"key":"3192_CR31","doi-asserted-by":"publisher","unstructured":"Formisano, E., Proietti, E., Borgarelli, C., & Pisciotta, L. Psoriasis and Vitamin D: A Systematic Review and Meta-Analysis.\u00a0Nutrients.\u00a02023; 15. https:\/\/doi.org\/10.3390\/nu15153387 .","DOI":"10.3390\/nu15153387"},{"key":"3192_CR32","doi-asserted-by":"crossref","unstructured":"Pokharel, R., Agrawal, S., Pandey, P. & Lamsal, M. Assessment of vitamin D level in patients with psoriasis and its correlation with disease severity: A case\u2013control study\u00a0(2022).","DOI":"10.2147\/PTT.S369426"},{"issue":"5","key":"3192_CR33","first-page":"400","volume":"58","author":"V Kulda","year":"2012","unstructured":"Kulda, V. Metabolizmus vitaminu D [Vitamin D metabolism]. Vnitr. Lek. 58(5), 400\u2013404 (2012).","journal-title":"Vnitr. Lek."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03192-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03192-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03192-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T02:50:50Z","timestamp":1748141450000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03192-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,25]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3192"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-03192-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4719372\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,25]]},"assertion":[{"value":"10 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"18175"}}